In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1 -altered NSCLC including: Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1 -altered advanced NSCLC Long-term safety observations for crizotinib and entrectinib CNS activity of entrectinib and repotrectinib in patients with brain metastases Repotrectinib activity in ROS1 -TKI resistance mutations Program faculty: Jessica J. Lin, MD Attending Physician Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Alice T. Shaw, MD, PhD Chief, Strategic Partnerships Attending Physician, Thoracic Oncology Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts Resources: To download the slides associated with this podcast discussion, please visit the program page . Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
